Wednesday, October 7, 2015 - 10:45

Exercise of Options

Clinigen Group plc (AIM: CLIN, ‘Clinigen’, or the ‘Group’) announces that it was notified on 6 October 2015 that on 6 October 2015 a total of 1,329,798 nil cost options over ordinary shares of 0.1 pence each in the Group (the “Options”) were exercised by the following directors:

Director Options Exercised
Peter George 825,556
Shaun Chilton 412,778
Peter Allen 91,464

 

The Options have been satisfied by shares from the Clinigen Group Employment Benefit Trust, which were subsequently sold in the market on 6 October 2015 at a price of 685 pence per share. As a result, there is no change in the shareholdings of the Directors listed above.

Sale of shares by Robin Sibson

In addition to the above exercise of Options, the Group was notified on 6 October 2015 that, on 6 October 2015, Robin Sibson, a director of the Group, sold a total of 1,000,000 ordinary shares of 0.1 pence each in the Group at a price of 685 pence per share. Following this sale of shares, Mr Sibson is interested in a total of 1,480,515 ordinary shares in the Group representing approximately 1.33 per cent. of the Group’s current issued share capital.

-Ends

 

Contact Details

Clinigen Group plc
Peter George, Group Chief Executive Officer
Shaun Chilton, Group Deputy CEO
Robin Sibson, Group Chief Financial Officer
Tel: +44 (0) 1283 495010

Numis Securities Limited
Michael Meade/Freddie Barnfield (Nominated Adviser)
James Black/Tom Ballard (Corporate Broking)

Tel: +44 (0) 20 7260 1000

Peel Hunt LLP
James Steel/Jock Maxwell Macdonald
Tel: +44 (0) 20 7418 8900

Instinctif Partners
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow
Tel: +44 (0) 20 7457 2020
Email: clinigen@instinctif.com 

 

Notes to Editors

About Clinigen Group

Clinigen Group is a global pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time. The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; through Clinigen CTS we manage the supply of commercial medicines for clinical trials, through Idis Managed Access we run early access programs for our own and other companies' portfolios, our Idis Global Access team works directly with healthcare providers to enable ethical compliant access to unlicensed medicines, and through Clinigen SP, we market our own portfolio of niche commercial products.

We are global leaders in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need.

For more information, please visit www.clinigengroup.com.

Back to News